Regulations.gov document
Reference 4 - Niazi SK. Contradicting rulings of the US patent office on double patenting…
Supporting & Related Material · FDA-2025-P-6763 · posted Dec 5, 2025
Key facts
| Document ID | FDA-2025-P-6763-0006 |
|---|---|
| Title | Reference 4 - Niazi SK. Contradicting rulings of the US patent office on double patenting jeopardize the generic and biosimilar drugs. Pharm Pat Anal. 2025;13(4–6):95–103. doi:10.1080/20468954.2025.2459582 |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2025-P-6763 |
| Posted | Dec 5, 2025 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: